Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03497572
Other study ID # 2017-A01797-46
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 25, 2017
Est. completion date April 12, 2018

Study information

Verified date May 2018
Source Imaxio
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aims to assess antibody persistence induced by Spirolept® vaccination in subjects who received at least 4 doses (2 doses two weeks apart and 2 booster doses) and no more than a total of 8 doses (2 doses two weeks apart and 6 booster doses).


Description:

This is a seroprevalence, phase IV, multi -center study to evaluate anti-Leptospira antibody persistence in subjects who have received at least the 2nd booster (4 vaccine doses) and no more than the 6th booster (8 vaccine doses) of Spirolept® vaccine.

The study will be conducted at the Occupational Health Centre of companies employing workers at risk of leptospirosis for their occupational activities. Study participants will be selected from the company Occupational Health Centre database where each employee is registered. All workers are regularly followed-up and their medical and vaccination history recorded. Subjects selection will occur according the number of booster doses received (having received at least the 2nd booster and no more than the 6th booster). After they have signed the informed consent form, subjects will be recruited into the study and if all inclusion and exclusion criteria are met they will be taken a blood sample.

Anti-leptospira IgG antibody will be measured by a validated ELISA. Other assay may be performed to further characterize anti-leptospira antibodies. Data on subject demographics, relevant medical history, vaccination dates, and blood collection will be recorded in an appropriate Case Report Form.

The study does not include any vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 145
Est. completion date April 12, 2018
Est. primary completion date April 12, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Adults of both genders aged 18 to 65 years

- High risk occupational subjects to leptospirosis having received at least 4 (2 initial doses and 2 booster doses) and no more than 8 (2 first doses and 6 booster doses) doses of Spirolept®

- Previous Spirolept® vaccination dates documented

- To be affiliated to a health insurance plan

- Having signed the informed consent form

Exclusion Criteria:

- Had an acute infection during the 3 weeks before study enrollment

- Subject with documented HIV or hepatitis A, B, C

- Immunosuppressive treatment (chemotherapy, corticosteroids > 20mg/day, biological agents)

- Subject with progressive malignancy requiring specific treatment

- Previous documented Leptospirosis

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France SIAAP Maisons-Laffitte
France Mairie de Paris Paris

Sponsors (1)

Lead Sponsor Collaborator
Imaxio

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other exploratory growth inhibition test (GIT) Test Proportion of subjects with positive GIT (positive GIT: serum that provides = 50% leptospira growth inhibition in the test) through study completion, an average of 8 months
Primary ELISA immunoglobulin G (IgG) anti-leptospire Proportion of subjects seropositive to ELISA IgG anti-leptospira (with cut-off antibody titer = 20) at different time points after the last booster dose through study completion, an average of 8 months
Secondary ELISA IgG geometric mean titer (GMTs) Proportion of subjects seropositive to ELISA IgG anti-leptospira (with cut-off antibody titer = 20) and GMTs at different time points according to demographic factors and vaccination scheme through study completion, an average of 8 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02898519 - Immune Response After Leptospirosis Infection N/A
Recruiting NCT05425524 - Leptospirosis Care Bundle Study N/A
Completed NCT03912506 - Severe Leptospirosis in Non-tropical Areas
Recruiting NCT04288674 - Leptospirosis Registry - LeptoScope
Recruiting NCT05300425 - Seroprevalence of Leptospirosis in Val Müstair, Switzerland
Completed NCT01080989 - The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands N/A
Recruiting NCT05436756 - Chronic Post-leptospirosis Manifestations in Reunion N/A
Recruiting NCT04882046 - Study of the Incidence of Jarisch-Herxheimer Reaction in Leptospirosis Patients in New Caledonia N/A
Terminated NCT00592566 - Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis Phase 2/Phase 3
Recruiting NCT04034550 - Cohort of Hospitalized Patients Suspected of Leptospirosis N/A
Completed NCT05413720 - Study of the Innate Immune Response to the Acute Phase of Human Leptospirosis - IMMUNOLEPTO N/A
Completed NCT01766830 - Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) N/A
Recruiting NCT02000635 - Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique
Active, not recruiting NCT01607047 - French West Indies Leptospirosis Study